Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Completed 7Terminated 4Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 4OTHER_GOV 1INDIV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Gastrointestinal 1

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 2capmatinib 1Radiotherapy, Intensity-Modulated 1Cisplatin 1Cetuximab 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Laryngeal Diseases × Clear all
NCT05386550 2026-02-19

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

EMD Serono

Phase 3 Terminated
166 enrolled 15 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Diseases

NCT06056310 2025-09-29

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

EMD Serono

Phase 1 Terminated
18 enrolled 9 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Diseases

NCT00198328 2022-03-04

Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma

Inovio Pharmaceuticals

Phase 3 Terminated
84 enrolled
Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Diseases, Neoplasms

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Novartis

Phase 1 Terminated
13 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡